GlaxoSmithKline News and Research

RSS

Researchers identify cellular mechanism associated with tinnitus

Researchers in the University of Leicester's Department of Cell Physiology and Pharmacology have identified a cellular mechanism that could underlie the development of tinnitus following exposure to loud noises. The discovery could lead to novel tinnitus treatments, and investigations into potential drugs to prevent tinnitus are currently underway.

10 May 2012

Guardian examines launch of GAVI-sponsored immunization campaign in Ghana

Ghana's recent "rollout of the rotavirus vaccine and, to much acclaim, a new vaccine against pneumococcal infections, makes it the first country in sub-Saharan African to introduce two new vaccines at the same time," the Guardian reports.

5 May 2012

NPS first quarter net loss increases to $10.6 million

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the first quarter of 2012.

4 May 2012

XenoPort first quarter revenues increase to $10.4 million

XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.

3 May 2012

Ligand first quarter total revenues increase to $5.6 million

Ligand Pharmaceuticals Incorporated today reported financial results for the first quarter ended March 31, 2012, and provided an operating forecast and program updates.

3 May 2012

Guardian, Malaria Consortium hold experts' roundtable discussion on World Malaria Day

The Guardian, in association with Malaria Consortium, hosted a roundtable discussion on World Malaria Day, during which participants heard about progress in the fight against the disease in certain countries and discussed how "the burden of malaria is still high and spending on the disease is inadequate," the Guardian reports.

27 Apr 2012

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

27 Apr 2012

Allied Healthcare increases stake in Coridon to over 44%

Allied Healthcare Group (ASX: AHZ) announced today that post the recent capital raising it has invested a further $1 million into Coridon, increasing its holding in the company to 44.4%. Allied has increased its investment in Coridon as the Company progresses towards its Phase I study for a herpes vaccine and makes further progress on its HPV therapeutic vaccine program.

26 Apr 2012

GSK, Epizyme and Constellation to develop next generation of epigenetic drugs for cancer

Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.

19 Apr 2012

Impax announces data from IPX066 Phase III study on Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28.

19 Apr 2012

GAVI Alliance secures deal to purchase rotavirus vaccines from GlaxoSmithKline, Merck

The GAVI Alliance "has struck a deal for bulk buying rotavirus shots from GlaxoSmithKline and Merck, which cuts the price by two-thirds and will allow poorer countries access to them at around $5 per course," Reuters reports.

12 Apr 2012

Fish oil not as beneficial for the heart as thought: Study

Fish oil, a combination of omega-3 fatty acids that has attracted much research on its effects on heart health. So far, the evidence has been inconclusive -- some studies have found fish oil has been major in preventing heart attacks, strokes and sudden cardiac death, while others have found fish oil has no benefits at all.

10 Apr 2012

Topline results from GSK's seven of eight albiglutide Phase 3 studies on type 2 diabetes

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that topline results have been received from seven of the eight Harmony Phase 3 studies investigating the use of albiglutide in type 2 diabetes.

4 Apr 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

FDA ODAC votes in favour of GSK's Votrient

GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.

21 Mar 2012

NMR techniques shed new light on how pharma molecules adopt different polymorphic forms

Scientists at the University of Warwick have used state-of-the-art nuclear magnetic resonance (NMR) techniques to shed new light on how pharmaceutical molecules pack together in the solid state.

8 Mar 2012

NJH to improve asthma care in Colorado's San Luis Valley

National Jewish Health has received a grant for $950,308 from GlaxoSmithKline to improve care of asthma patients in Colorado's San Luis Valley with educational materials for patients and hands-on training for primary health care teams.

29 Feb 2012

GSK, Angiochem to develop and commercialize LSD treatments

Angiochem announced today a global collaboration with GlaxoSmithKline (GSK) to discover, develop and commercialize treatments for lysosomal storage diseases.

27 Feb 2012

Impax announces FDA acceptance of NDA filing for IPX066

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for IPX066 for the treatment of idiopathic Parkinson's disease (PD) submitted to the Agency on December 21, 2011.

23 Feb 2012

AAN announces recipients of 2012 scientific research awards

Nearly two dozen scientific research awards are being bestowed on researchers around the world this year by the American Academy of Neurology, the world's largest association of neurologists. The awards will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21-28, 2012, at the New Orleans Ernest N. Morial Convention Center.

22 Feb 2012